Celcuity (CELC) Return on Capital Employed (2017 - 2025)
Celcuity (CELC) posted Return on Capital Employed of 40.31% for Q4 2025, up 26.41% on a QoQ basis from 54.78% in Q3 2025, and up 951.0% year-over-year from 3.84% in Q4 2024.
Celcuity (CELC) Return on Capital Employed (2017 - 2025) Analysis & Trends
Celcuity's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 40.31% for Q4 2025.
- Quarterly Return on Capital Employed rose 951.0% year-over-year to 40.31% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 40.31% (up 951.0% YoY) and the FY2025 annual result came in at 55.24%, up 550.0% from the prior year.
- Return on Capital Employed was 40.31% for Q4 2025 at Celcuity, up from 54.78% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.01% in Q1 2023 and bottomed at 91.12% in Q2 2025.
- A 5-year average of 45.4% and a median of 42.2% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed soared 4212 bps — and 2025, when it plunged 5245 bps.
- Celcuity's Return on Capital Employed stood at 32.83% in 2021, then declined by 6 bps to 34.67% in 2022, then fell by 25 bps to 43.4% in 2023, then declined by 15 bps to 49.82% in 2024, then gained by 19 bps to 40.31% in 2025.
- Business Quant data shows CELC's Return on Capital Employed at 40.31% in Q4 2025, 54.78% in Q3 2025, and 91.12% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Celcuity | 4.13 Bn | 4.13 Bn | - | -40.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -40.31% |
| Sep 30, 2025 | -54.78% |
| Jun 30, 2025 | -91.12% |
| Mar 31, 2025 | -63.87% |
| Dec 31, 2024 | -49.82% |
| Sep 30, 2024 | -37.65% |
| Jun 30, 2024 | -38.67% |
| Mar 31, 2024 | -44.03% |
| Dec 31, 2023 | -43.40% |
| Sep 30, 2023 | -42.99% |
| Jun 30, 2023 | -32.79% |
| Mar 31, 2023 | -27.01% |
| Dec 31, 2022 | -34.67% |
| Sep 30, 2022 | -54.80% |
| Jun 30, 2022 | -40.32% |
| Mar 31, 2022 | -41.67% |
| Dec 31, 2021 | -32.83% |
| Sep 30, 2021 | -38.12% |
| Jun 30, 2021 | -56.41% |
| Mar 31, 2021 | -42.73% |